Physician profile
Ronald Ambe
NPI 1063688711
$2,111.80
in general payments reported to CMS, 2019-2025
11 companies · $28.14 in 2025
The $28.14 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $425 · 2021: $649 · 2022: $50.53 · 2023: $205 · 2024: $27.88 · 2025: $28.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,376.74 | 2019-2021 | |
| Covidien LP | $325.00 | 2020 | |
| Boston Scientific Corporation | $201.41 | 2023-2025 | Wavewriter Alpha Prime 16, Resolution 360 Clip |
| Tela Bio, INC. | $60.98 | 2019-2024 | Ovitex 2s |
| Ethicon US, LLC | $30.05 | 2020 | |
| Medtronic, INC. | $25.87 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.66 | 2022 | |
| Baudax Bio INC. | $21.79 | 2021 | |
| Exact Sciences Corporation | $16.50 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.31 | 2023 | Xifaxan |
| Thd America, INC. | $13.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ambe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.